Canagliflozin tablets obtain drug registration certificate
October 28, 2025
Source: drugdu
77
Southern Finance reported on October 27 that Huahai Pharmaceutical(600521) announced on October 27 that the company recently received the "Drug Registration Certificate" for canagliflozin tablets approved and issued by the State Food and Drug Administration. This product is used in combination with metformin hydrochloride: when blood sugar control is poor with metformin hydrochloride alone, it can be used in combination with metformin hydrochloride, combined with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes; this product is used in combination with metformin hydrochloride and sulfonylurea drugs: when blood sugar control is poor with the combination of metformin hydrochloride and sulfonylurea drugs, it can be used in combination with metformin hydrochloride and sulfonylurea drugs, combined with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes.
Source：https://finance.eastmoney.com/a/202510273545770287.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
